Search results for "TUBERCULOSIS"

showing 10 items of 303 documents

Determination of isoniazid and pyridoxine in plasma sample of tuberculosis patients by micellar liquid chromatography

2021

It is no doubt Isoniazid is a powerful tuberculosis drug, but it might give rise to Vitamin B6 (Pyridoxine) deficiency. In this case, a usual treatment is the combined administration of Isoniazid and Pyridoxine. An easy-to-conduct procedure based on Micellar Liquid Chromatography has been developed to quantify Isoniazid and Pyridoxine in plasma from Tuberculosis patients. The sample was diluted in mobile phase, filtered and directly injected, thus avoiding extraction or purification steps. Both drugs were adequately resolved from the matrix and endogenous compounds using a mobile phase made up of 0.15 M sodium dodecyl sulfate – 8%(v/v) 1-butanol – 0.01 M phosphate buffer at pH 3, running at…

DrugBioanalysismedia_common.quotation_subjectmicellar02 engineering and technology01 natural sciencespatientsAnalytical ChemistryMatrix (chemical analysis)chemistry.chemical_compoundmedicineantituberculosisSodium dodecyl sulfateSpectroscopyplasmamedia_commonChromatographyChemistry010401 analytical chemistryExtraction (chemistry)Isoniaziddrug021001 nanoscience & nanotechnologyPyridoxine0104 chemical sciencesMicellar liquid chromatography0210 nano-technologyoptimizationmedicine.drug
researchProduct

The zebrafish embryo as an in vivo model for screening nanoparticle-formulated lipophilic anti-tuberculosis compounds.

2021

ABSTRACT With the increasing emergence of drug-resistant Mycobacterium tuberculosis strains, new and effective antibiotics against tuberculosis (TB) are urgently needed. However, the high frequency of poorly water-soluble compounds among hits in high-throughput drug screening campaigns is a major obstacle in drug discovery. Moreover, in vivo testing using conventional animal TB models, such as mice, is time consuming and costly, and represents a major bottleneck in lead compound discovery and development. Here, we report the use of the zebrafish embryo TB model for evaluating the in vivo toxicity and efficacy of five poorly water-soluble nitronaphthofuran derivatives, which were recently id…

DrugIn vivo efficacyTuberculosismedicine.drug_classmedia_common.quotation_subjectAntibioticsAntitubercular AgentsNeuroscience (miscellaneous)Medicine (miscellaneous)Anti-tuberculosis drugsPharmacologyBiologyGeneral Biochemistry Genetics and Molecular BiologyMycobacterium tuberculosisMiceImmunology and Microbiology (miscellaneous)In vivoZebrafish as a Disease ModelmedicineAnimalsTuberculosisZebrafishmedia_commonIn vivo toxicityDrug discoveryMycobacterium tuberculosismedicine.diseasebiology.organism_classificationIn vitroZebrafish tuberculosis modelDrug developmentNanoparticlesResearch Article
researchProduct

Nanocarriers for respiratory diseases treatment: Recent advances and current challenges

2014

Pulmonary delivery of locally-acting drugs encapsulated in nanocarriers provides several advantages for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary diseases, cystic fibrosis, tuberculosis and lung cancer. These advantages include, among others, sustained drug delivery to the lungs, reduced therapeutic dose and improved patient compliance. The aim of this review is to give an updated overview on recent advances recorded in the last few years in this field as well as on the major challenges still existing and that remain to be overcome before any clinical application. After an outline on the cellular and extracellular barriers affecting drug delivery to…

Drugmedicine.medical_specialtymedia_common.quotation_subjectpulmonary deliveryAntitubercular AgentsMicrobial Sensitivity TestsGene deliveryPharmacologyCystic fibrosisTherapeutic indexDrug DiscoverymedicineAnimalsHumansTuberculosisIntensive care medicinemedia_commonDrug CarriersLungrespiratory diseasesbusiness.industryMycobacterium tuberculosisGeneral Medicinemedicine.diseaseinhalation of polymeric- and lipid-based nanocarriermedicine.anatomical_structurelung targetingTargeted drug deliveryDrug deliverymucus penetrationNanoparticlesNanocarriersbusinessDefense mechanism
researchProduct

Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Devel…

2020

BACKGROUND: Sustainable Development Goal (SDG) 3 aims to "ensure healthy lives and promote well-being for all at all ages". While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available. METHODS: We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For …

Economic growthFinancing GovernmentPsychological interventionHIV Infectionsburden of disease030204 cardiovascular system & hematologyDISEASEALLOCATION0302 clinical medicineRA0421RA0421 Public health. Hygiene. Preventive MedicineSustainable developmentGlobal healthhealth economicsHealthcare FinancingHIV Infection030212 general & internal medicine10. No inequality11 Medical and Health SciencesDALYHealthy lives1. No povertyPublic Health Global Health Social Medicine and Epidemiology3rd-DASGeneral MedicineSustainable Development3. Good healthtuberculosisIMPOVERISHMENTTERRITORIESFinancingHumanFinancing PersonalResource (biology)Tuberculosi195 COUNTRIESDeveloping Countrie03 medical and health sciencesSDG 3 - Good Health and Well-beingAcquired immunodeficiency syndrome (AIDS)General & Internal MedicineSYSTEMATIC ANALYSISmedicineHumansBurden HIV/AIDS tubercolosis malariaHuman resourcesDeveloping CountriesSustainable developmentGovernmentAcquired Immunodeficiency SyndromeHealth economicsbusiness.industryDISABILITYCATASTROPHEGlobal Burden of Disease Health Financing Collaborator NetworkGLOBAL BURDENmedicine.diseaseMalariaSDG; health sector spending; development assistant for health.Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineNAHealth ExpendituresbusinessEXPENDITURE
researchProduct

Saving Technologies that are not Used to Save Lives

2021

A hundred years ago in July, thanks to the advancement of medical technology, the first human received the vaccine Bacille Calmette-Guérin—or BCG—to prevent tuberculosis (TB), a disease that killed at least 20% of the European population during the 19th century. Since then, hundreds of millions of lives have been saved by BCG, as well as other vaccinations for dangerous diseases. However, although TB is quite preventable and curable, it remains the leading cause of death from a single infectious agent in the world. It is an example of how humans can invent technologies to improve and save lives but fail to do so because of unevenly distributed resources, lack of media coverage, and other ec…

Economic growthTuberculosisSocial PsychologyCommunicationHealth technologyDiseasemedicine.diseaseHuman-Computer InteractionVaccinationPoliticsmedicineLife savingCause of deathInfectious agentHuman Technology
researchProduct

Homing and memory patterns of human gammadelta T cells in physiopathological situations.

2004

Vgamma9Vdelta2 are a heterogeneous population of T cells and comprise distinct naive, memory and effector populations that can be distinguished on the basis of surface marker expression and effector functions. We review here these recently studied features of Vgamma9Vdelta2 T lymphocyte biology and the roles they play in infectious and autoimmune diseases.

EffectorImmunologyT lymphocyteBiologymedicine.disease_causeInfectionsLymphocyte ActivationMicrobiologyAutoimmunityAutoimmune DiseasesHeterogeneous populationInfectious DiseasesT-Lymphocyte SubsetsSurface markerImmunologymedicineHumansTuberculosisEffector functionsMalaria FalciparumProtozoal diseaseImmunologic MemoryHoming (hematopoietic)Microbes and infection
researchProduct

A case of disseminated BCG infection in a daughter of Italian immigrants in Switzerland

2022

Bacillus Calmette-Guérin (BCG) is a vaccine against tuberculosis and contains a live, attenuated strain of Mycobacterium bovis as its essential constituent. Being a live, attenuated strain with potential pathogenicity, BCG can cause different complications, both near the inoculation site and through blood dissemination, especially in patients with immunodeficiency. IFN-γR1 deficiency is an autosomal recessively inherited immunodeficiency characterized by predisposition to infections with intracellular pathogens, in particular mycobacteria.
 We report a rare case of chronic osteomyelitis lasting 30 years due to BCG in a woman with IFN-γR1 deficiency who had previous clinical history of …

Emigrants and ImmigrantsDisseminated BCG infectionEmigrants and ImmigrantGeneral MedicinedeficiencyMicrobiologyNuclear FamilyInfectious DiseasesIFN-γR1VirologyPositron Emission Tomography Computed TomographyBCG VaccineHumansTuberculosisParasitologyFemaleChildTuberculosis.SwitzerlandHuman
researchProduct

Quantifying transmission fitness costs of multi-drug resistant tuberculosis.

2021

As multi-drug resistant tuberculosis (MDR-TB) continues to spread, investigating the transmission potential of different drug-resistant strains becomes an ever more pressing topic in public health. While phylogenetic and transmission tree inferences provide valuable insight into possible transmission chains, phylodynamic inference combines evolutionary and epidemiological analyses to estimate the parameters of the underlying epidemiological processes, allowing us to describe the overall dynamics of disease spread in the population. In this study, we introduce an approach to Mycobacterium tuberculosis (M. tuberculosis) phylodynamic analysis employing an existing computationally efficient mod…

EpidemiologyComputer scienceAntibiotic resistance030231 tropical medicinePopulationAntitubercular AgentsInferenceInfectious and parasitic diseasesRC109-216Drug resistanceComputational biologyMicrobial Sensitivity TestsMicrobiologylaw.inventionMycobacterium tuberculosis03 medical and health sciencesMulti-type birth–death model0302 clinical medicinelawVirologyMulti-type birth-death modelTuberculosis Multidrug-ResistantmedicineHumans030212 general & internal medicineWhole genome M. tuberculosiseducationEpidemicsPhylogenyeducation.field_of_studybiologyPhylogenetic treeMulti-drug-resistant tuberculosisPublic Health Environmental and Occupational HealthAntibiotic resistance; Multi-type birth–death model; Phylodynamics; Whole genome M. tuberculosisMycobacterium tuberculosismedicine.diseasebiology.organism_classificationPhylodynamics614: Public Health und GesundheitsförderungInfectious DiseasesViral phylodynamicsTransmission (mechanics)ParasitologyEpidemics
researchProduct

Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection.

2017

Introduction RD1-based Interferon-γ Release Assays (IGRAs) cannot distinguish latent from active tuberculosis (TB) disease. Conversely, a positive response to heparin-binding haemagglutinin (HBHA)-based IGRAs, among TB-infected subjects, correlates with Mycobacterium tuberculosis (Mtb) containment and low risk of TB progression. The aim of this study was to characterize HBHA-immune responses in HIV-infected and uninfected subjects with active TB or latent TB infection (LTBI). Methods 49 subjects were prospectively enrolled: 22 HIV-uninfected (13 TB, 9 LTBI) and 27 HIV-infected (12 HIV-TB, 15 HIV-LTBI). Whole blood and peripheral blood mononuclear cells were stimulated with HBHA and RD1 anti…

Genetics and Molecular Biology (all)0301 basic medicineBacterial DiseasesRNA virusesCD4-Positive T-LymphocytesMalePhysiologylcsh:MedicineHIV InfectionsCD8-Positive T-LymphocytesPathology and Laboratory MedicineBiochemistryMemory T cellsWhite Blood CellsImmunodeficiency VirusesInterferonAnimal CellsImmune PhysiologyLectinsMedicine and Health SciencesProspective Studieslcsh:ScienceInnate Immune SystemMultidisciplinarybiologyT CellsInterleukinvirus diseasesMiddle AgedFlow Cytometry3. Good healthActinobacteriaInfectious DiseasesMedical MicrobiologyViral PathogensVirusesDisease ProgressionCytokinesFemaleCellular TypesPathogensmedicine.drugResearch ArticleAdultTuberculosisImmune CellsImmunologyCytotoxic T cellsEnzyme-Linked Immunosorbent AssayPeripheral blood mononuclear cellMicrobiologySettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAMycobacterium tuberculosis03 medical and health sciencesInterferon-gammaImmune systemAntigenRetrovirusesmedicineTuberculosisHumansMicrobial PathogensAdult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; HIV Infections; Humans; Interferon-gamma; Lectins; Male; Middle Aged; Prospective Studies; Tuberculosis; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Blood CellsBacteriaLentiviruslcsh:ROrganismsBiology and Life SciencesProteinsHIVCell BiologyMolecular Developmentbiology.organism_classificationmedicine.diseaseTropical DiseasesVirology030104 developmental biologyAgricultural and Biological Sciences (all)Immune SystemImmunologylcsh:QInterferonsCD8Mycobacterium TuberculosisDevelopmental BiologyPLoS ONE
researchProduct

Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique.

2018

Abstract Objective Tuberculosis (TB) remains a major global health issue, ranking in the top ten causes of death worldwide. A deep understanding of factors influencing poor treatment outcomes may allow the development of additional treatment strategies, focused on the most vulnerable groups. Aims of the study were: (i) to evaluate the treatment outcome among TB subjects followed in an outpatient setting and (ii) to analyze factors associated with treatment failure in newly diagnosed patients with pulmonary TB in Beira, the second largest city of Mozambique. Results A total of 301 TB adult patients (32.6% females) were enrolled. Among them, 62 (20.6%) experienced a treatment failure over a 6…

Genetics and Molecular Biology (all)0301 basic medicineMaleTreatment outcomeAntitubercular Agentslcsh:MedicineHIV InfectionsSettore MED/42 - Igiene Generale E ApplicataBiochemistryTreatment failureBody Mass Index0302 clinical medicineTherapy failureOutpatientsGlobal healthOdds Ratio030212 general & internal medicineTreatment Failurelcsh:QH301-705.5MozambiqueCoinfectionGeneral MedicinePrognosisMozambique; Therapy failure; Tuberculosis; Biochemistry Genetics and Molecular Biology (all)Research NoteEducational StatusFemaleAdultEmploymentmedicine.medical_specialtyTuberculosisAdolescent030106 microbiologyNewly diagnosedGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesPulmonary tuberculosisInternal medicinemedicineHumansTuberculosislcsh:Science (General)PovertyTuberculosis PulmonaryAdult patientsbusiness.industrylcsh:RMalnutritionmedicine.diseaseTuberculosis Mozambique Therapy failurelcsh:Biology (General)Hiv statusbusinesslcsh:Q1-390BMC research notes
researchProduct